Last updated: June 9, 2026
Potassium chloride (KCl) supplied in plastic containers is sourced across two tracks: (1) finished sterile products in plastic systems (IV fluids or injection concentrates) and (2) bulk KCl drug substance plus container manufacturing/packaging conversion. The most reliable supplier set for procurement is the list of FDA-registered manufacturers marketing KCl products in plastic containers, because product-specific container system and labeling drive regulatory eligibility.
Which companies supply potassium chloride in plastic containers for IV use?
The practical supplier universe for “potassium chloride in plastic container” in the US is the set of FDA-approved label holders and their manufacturing partners for sterile KCl strengths and dosage forms shipped in plastic packaging.
What product lines are typically considered “potassium chloride in plastic container”?
Searches for this phrase usually map to one of these SKUs:
- Potassium chloride injection (sterile) packaged in plastic vials or plastic infusion containers
- Potassium chloride in IV solutions (as an additive component), shipped in plastic infusion bags
- Oral liquid potassium chloride in plastic bottles (less common in “plastic container” procurement language, but often included)
Which suppliers appear most often in procurement workflows?
Procurement lists typically separate:
- Finished-dose manufacturers (hold the NDA/ANDA and ship finished KCl in plastic containers)
- Private label/contract manufacturers that produce for distributors or label holders
- Container system suppliers (manufacture the plastic packaging and sometimes the filled system)
Because supplier status is product- and container-system specific, the supplier answer for “plastic container KCl” is best anchored to Orange Book / FDA label listings for each dosage form and concentration.
What container types matter for potassium chloride in plastic systems?
Commercial purchasing usually distinguishes:
- Plastic vials / ampules (sterile single-dose)
- Plastic infusion bags (multi-dose IV)
- Blister packs (not a “plastic container” in the IV context)
- Oral plastic bottles (HDPE/PP closures)
What container and packaging formats are used for potassium chloride in plastic containers?
Container format affects leachables, compatibility testing, stability, and shipping constraints.
IV plastic packaging: bag vs. vial
- Infusion bags are used for KCl added to IV fluids or KCl infusion products.
- Plastic vials are used for KCl injection units where nurses draw/transfer into administration sets.
What stability and compatibility drivers apply to KCl plastic packaging?
- Plastic composition (polyolefin types), barrier properties, and closure chemistry
- Trace moisture uptake and adsorption effects on formulation components (if present)
- Leachables/extractables controls in qualification and ongoing stability programs
How do supplier eligibility and regulatory status work for KCl in plastic containers?
For procurement and compliance, suppliers must match:
- The FDA-approved labeling for the dosage form and container
- The application type (NDA vs ANDA) for generic or follow-on versions
- The container listing in FDA/label documents for the specific SKU
What is the Orange Book status of potassium chloride products in plastic containers?
KCl is a foundational drug with many generics, so the Orange Book typically lists multiple approved ANDAs for injection products and oral solutions. The determining factor for “plastic container” is whether each ANDA lists the relevant container system in the approved description and labeling.
How does FDA listing affect sourcing?
- Only manufacturers with an approved application for the exact dosage form and strength can supply a therapeutically equivalent product under that labeling.
- Contract manufacturers may be involved, but the marketing authorization holder is what drives FDA compliance and substitution.
What patents or litigation affect potassium chloride supplied in plastic containers?
For KCl, patents are generally less determinative than for newer small molecules, because many products are established and generic competition is mature. The sourcing issue is usually not freedom-to-operate for KCl as an active ingredient, but:
- Product-specific formulation or packaging patents (less common in simple KCl injection)
- Container system compatibility and manufacturing method claims (rare but possible)
- Supply-side litigation that blocks a subset of products or strengths
In practice, procurement risk is more likely tied to:
- Recalls and quality notifications
- Manufacturing downtime or sterility failures
- Allocation/shortage status for specific strengths or container sizes
Which supply chain constraints affect potassium chloride availability in plastic containers?
KCl shortages tend to be driven by capacity and sterility/quality issues rather than active-ingredient scarcity, since KCl is widely available as bulk chemical.
What constraints most often tighten supply?
- Sterile manufacturing capacity for injection and infusion products
- Container supply for specific bag or vial geometries
- Sterility assurance and batch release throughput
- Regulatory quality actions that temporarily pause shipments for particular lots or strengths
How many suppliers can cover potassium chloride in plastic containers by dosage form?
Coverage can be segmented as follows for sourcing planning:
- Injection / infusion (sterile): multiple ANDA/label holders, but fewer active manufacturers with validated sterile lines and packaging qualification
- Oral solution / extended release oral forms: broader non-sterile supply base, more bottle and oral-liquid packaging coverage
For allocation planning, procurement teams typically build a shortlist by:
- dosage form and strength
- container size and configuration
- number of approved sources on the FDA/Orange Book record
- historical fill-rate and lead times
Supplier shortlist structure for purchasing KCl in plastic containers (what to ask vendors)
A sourcing-ready RFQ package should include:
- Product: exact KCl concentration, dosage form (injection/infusion/oral)
- Container: plastic type (bag vs vial), fill volume, and closure system
- Regulatory: the ANDA/NDA number tied to that SKU
- Supply terms: minimum order quantity, lead time, and cold-chain requirements (usually none for KCl unless combined with other actives)
Key Takeaways
- The most actionable “supplier list” for KCl in plastic containers is built from approved FDA/Orange Book product records tied to the exact dosage form, strength, and plastic container system.
- Supply is concentrated in the sterile manufacturing + qualified plastic packaging segment for injection/infusion; bottling and non-sterile forms generally have wider supplier coverage.
- Purchasing and substitution risk is driven more by SKU-level container listing, FDA labeling, and lot release/quality events than by active-ingredient patent barriers.
FAQs
1) What dosage forms of potassium chloride are commonly shipped in plastic containers?
Sterile KCl injection/infusion and oral KCl solutions are the most common matches for “plastic container” language, with the sterility segment dominating procurement sensitivity.
2) Can I substitute one potassium chloride plastic-container SKU for another?
Substitution depends on the FDA-approved product description, which includes container system and labeling for that strength and dosage form.
3) What drives potassium chloride injection shortages most often?
Typically sterile manufacturing capacity, batch release, and quality events, with container supply constraints as a secondary driver for specific strengths.
4) Do container types (bag vs vial) change the supplier eligibility?
Yes. Bag vs vial is tied to qualification, stability/compatibility, and labeling, so approved sourcing is usually SKU- and container-specific.
5) Are potassium chloride packaging and method patents a major barrier to generic supply?
For most established KCl products, generic competition is mature; barriers are more often practical (quality/sterile lines, container system qualification) than patent-driven, though product-specific exclusions can exist.
References
- US FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA database). https://www.accessdata.fda.gov/scripts/cder/daf/
- US FDA, Drugs@FDA. (FDA database). https://www.accessdata.fda.gov/scripts/cder/daf/
